Mirtazapine Viatris

Mirtazapine, the active ingredient in Mirtazapine Viatris, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients. It is formulated for convenient once‑daily dosing and is marketed across the European Union.

GNH USA supplies Mirtazapine Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Mirtazapine acts on the central nervous system to treat depressive disorders. - Major depressive disorder: reduces depressive symptoms and improves overall mood in adult patients.

Mirtazapine may cause a range of adverse reactions.

Common Side Effects: - Sedation: feeling unusually sleepy or drowsy. - Increased appetite: often leading to weight gain. - Dry mouth: reduced salivation causing discomfort. - Constipation: difficulty passing stools.

Serious or Rare Side Effects: - Agranulocytosis: severe drop in white blood cells. - Suicidal ideation: emergence or worsening of suicidal thoughts. - Serotonin syndrome: potentially life‑threatening condition when combined with other serotonergic agents. - Severe hypotension: marked drop in blood pressure.

Before initiating therapy, consider the following precautions. - Assess hepatic function: adjust use in patients with severe liver impairment. - Monitor for suicidal thoughts: especially during the first weeks of treatment. - Caution in elderly: increased risk of sedation, falls, and weight gain. - Avoid abrupt discontinuation: taper dose to reduce withdrawal symptoms. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Mirtazapine can interact with several drug classes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other serotonergic agents (e.g., SSRIs, SNRIs): potential serotonin syndrome. - CNS depressants (e.g., benzodiazepines, alcohol): enhanced sedation.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine levels. - Carbamazepine: may reduce mirtazapine exposure, requiring dose adjustment.